Back to Report Store Home

Hereditary Hematological Disorders Drug Development Pipeline Review, 2018

  • Published: Oct-2018
  • Report Code: GBIHC048IDB
  • Report Format: pdf

Description

List of Figures

Figure 1: Number of Products under Development for Thalassemia

Figure 2: Number of Products under Development by Companies, Thalassemia

Figure 3: Number of Products under Development by Universities/Institutes, Thalassemia

Figure 4: Number of Products under Development for Hemophilia B

Figure 5: Number of Products under Development by Companies, Hemophilia B

Figure 6: Number of Products under Development by Universities/Institutes, Hemophilia B

Figure 7: Number of Products under Development for Sickle Cell Disease

Figure 8: Number of Products under Development by Companies, Sickle Cell Disease

Figure 9: Number of Products under Development by Universities/Institutes, Sickle Cell Disease

Figure 10: Number of Products by Top 10 Targets, Thalassemia

Figure 11: Number of Products by Stage and Top 10 Targets, Thalassemia

Figure 12: Number of Products by Top 10 Mechanism of Actions, Thalassemia

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Thalassemia

Figure 14: Number of Products by Routes of Administration, Thalassemia

Figure 15: Number of Products by Stage and Routes of Administration, Thalassemia

Figure 16: Number of Products by Molecule Types, Thalassemia

Figure 17: Number of Products by Stage and Molecule Types, Thalassemia

Figure 18: Number of Products by Targets, Hemophilia B

Figure 19: Number of Products by Stage and Targets, Hemophilia B

Figure 20: Number of Products by Mechanism of Actions, Hemophilia B

Figure 21: Number of Products by Stage and Mechanism of Actions, Hemophilia B

Figure 22: Number of Products by Routes of Administration, Hemophilia B

Figure 23: Number of Products by Stage and Routes of Administration, Hemophilia B

Figure 24: Number of Products by Molecule Types, Hemophilia B

Figure 25: Number of Products by Stage and Molecule Types, Hemophilia B

Figure 26: Number of Products by Top 10 Targets, Sickle Cell Disease

Figure 27: Number of Products by Stage and Top 10 Targets, Sickle Cell Disease

Figure 28: Number of Products by Top 10 Mechanism of Actions, Sickle Cell Disease

Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Sickle Cell Disease

Figure 30: Number of Products by Routes of Administration, Sickle Cell Disease

Figure 31: Number of Products by Stage and Routes of Administration, Sickle Cell Disease

Figure 32: Number of Products by Top 10 Molecule Types, Sickle Cell Disease

Figure 33: Number of Products by Stage and Top 10 Molecule Types, Sickle Cell Disease

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards